Actinium Pharmaceuticals (ATNM) News Today $1.76 -0.02 (-1.12%) Closing price 04:00 PM EasternExtended Trading$1.77 +0.01 (+0.57%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals SummitJuly 31, 2025 | prnewswire.comActinium Pharmaceuticals (NYSE:ATNM) Shares Up 7.7% - Time to Buy?July 23, 2025 | marketbeat.comATNM - Actinium Pharmaceuticals Inc Price vs Fair Value | MorningstarJuly 10, 2025 | morningstar.comMActinium Highlights ATNM 400 Progress at SNMMI ConferenceJuly 2, 2025 | insidermonkey.comATNM - Actinium Pharmaceuticals Inc Chart - MorningstarJune 28, 2025 | morningstar.comMInvestors Bet on Biotech as Public Cancer Research Hits a WallJune 26, 2025 | baystreet.caActinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual MeetingJune 23, 2025 | prnewswire.comKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law FirmJune 10, 2025 | prnewswire.comATNM DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities ...May 29, 2025 | stockhouse.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 26, 2025 | globenewswire.comATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025May 26, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 26, 2025 | prnewswire.comATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 26, 2025 | prnewswire.comATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNMMay 25, 2025 | globenewswire.comATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About ...May 25, 2025 | morningstar.comMATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their RightsMay 23, 2025 | businesswire.comClass Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & KorsinskyMay 23, 2025 | prnewswire.comShareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreMay 22, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 22, 2025 | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNMMay 22, 2025 | prnewswire.comATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 21, 2025 | prnewswire.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 21, 2025 | globenewswire.comATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitMay 20, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 20, 2025 | prnewswire.comInvestors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNMMay 20, 2025 | prnewswire.comROSEN, A TOP RANKED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNMMay 19, 2025 | globenewswire.comATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMay 19, 2025 | globenewswire.comContact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM)May 19, 2025 | prnewswire.comActinium Pharmaceuticals, Inc. (ATNM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 27, 2025 DeadlineMay 18, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 18, 2025 | globenewswire.comATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLPMay 18, 2025 | globenewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNMMay 17, 2025 | markets.businessinsider.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 16, 2025 | prnewswire.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 16, 2025 | globenewswire.comInvestor Alert: Deadline Approaching to Join Actinium Pharmaceuticals, Inc. (ATNM) Class Action - Contact Levi & KorsinskyMay 16, 2025 | markets.businessinsider.comInvestors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class Action - ATNMMay 16, 2025 | globenewswire.comActinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNMMay 16, 2025 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNMMay 15, 2025 | globenewswire.comClass Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law FirmMay 15, 2025 | prnewswire.comKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law FirmMay 14, 2025 | globenewswire.comActinium Pharmaceuticals, Inc. (ATNM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 27, 2025 DeadlineMay 14, 2025 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumMay 14, 2025 | globenewswire.comClass Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join – Contact Levi & KorsinskyMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 13, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming DeadlineMay 13, 2025 | prnewswire.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 12, 2025 | gurufocus.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 12, 2025 | prnewswire.comShareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreMay 12, 2025 | globenewswire.comActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact ...May 12, 2025 | gurufocus.com Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATNM Media Mentions By Week ATNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATNM News Sentiment▼0.000.97▲Average Medical News Sentiment ATNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATNM Articles This Week▼08▲ATNM Articles Average Week Get the Latest News and Ratings for ATNM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Actinium Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Aerovate Therapeutics News Contineum Therapeutics News Voyager Therapeutics News Heron Therapeutics News Lyell Immunopharma News Aclaris Therapeutics News Innate Pharma News Ventyx Biosciences News Entrada Therapeutics News GENFIT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ATNM) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access